3 Hidden-Gem Stocks Flying Under the Radar in 2026

Everyone's staring at the same six tickers right now. Fair enough, the macro circus is impossible to ignore. But while retail is piling into Mag Seven names and doom-scrolling oil charts, a handful of small and mid-cap companies are doing something quietly interesting. Here are three worth knowing before everyone else does.

$HUT already got its moment in the spotlight last week with that $27 billion in contracted AI revenue milestone, so we're not going back there. Instead, let's talk about Hims and Hers Health ($HIMS), the telehealth and compounding pharmacy play trading on NYSE. The company has been quietly expanding its GLP-1 weight-loss drug access business at a time when traditional pharmacy chains are stumbling. It's under a $3 billion market cap, covers a sticky recurring-revenue subscription model, and operates in a regulatory gray zone that creates both risk and a serious moat. The catalyst to watch: any FDA ruling on compounded semaglutide access either blows the door off its hinges or slams it shut, so the binary here is real. The bull case is a massive addressable market with very low customer acquisition costs once patients are in the funnel. The bear case is exactly one unfavorable regulatory headline away from a very bad afternoon.

Rocket Lab USA ($RKLB) showed up in Bloomberg's Stock Movers coverage this week with a 4.2% premarket gain, but it's still not getting the full credit it deserves for being the only credible alternative to SpaceX for small satellite launches. With a market cap hovering below $8 billion, it sits comfortably in mid-cap territory and has been quietly expanding its Neutron rocket development timeline. The geopolitical backdrop actually helps here: defense and intelligence agency demand for rapid, reliable small satellite deployment doesn't slow down during a US-Iran conflict, it accelerates. Revenue growth has been double-digit consecutive, and the company has a growing space systems segment that's less cyclical than launch revenue alone. The risk is that SpaceX's Falcon 9 keeps undercutting on price and timeline, which is not a small risk when your competitor is basically a government contractor moonlighting as a private company.

Hut 8 ($HUT) is technically on the recently covered list, but the $10 billion lease with an unnamed hyperscaler story hasn't been fully digested. Most coverage focused on the stock pop, not on what a 15-year committed lease means for recurring EBITDA visibility. At roughly $1.75 billion in annual EBITDA against a market cap that was still sub-$5 billion before the news, the discount to fair value was genuinely striking. That gap has started to close but may not be done closing. The pivot from crypto miner to AI infrastructure host is one of the more complete business model transformations in recent memory, and it's still trading like a meme stock with volatility to match.

The thread connecting all three: they're operating in infrastructure or access layers of massive themes (AI compute, weight-loss drugs, space launch) where the incumbents are either private or too large to move fast. The best hidden gems aren't hiding in obscure industries. They're hiding in plain sight behind louder, flashier names that suck up all the oxygen in the room.